The US FTC seeks divestiture of rights and assets to five different medications before approving a merger affecting the markets for generic injectable pharmaceuticals (Hospira / Mayne)

The FTC entered into a consent decree with Hospira Inc. and Mayne Pharma Ltd. on May 21, 2007 imposing divestitures on the firms prior to clearing their merger. The consent decree required Mayne to divest its current business in one type of generic pharmaceuticals, as well as the assets related to its imminent entrance into the markets for four other generic pharmaceuticals. The FTC imposed the divestiture with the goal of preserving the same level of competition in those five markets after the acquisition of Mayne. Hospira and Mayne represented two of only three suppliers in the market for the generic injectable pharmaceutical, hydromorphone hydrochloride. Hydromorphone is a Schedule II narcotic, used to ease patients’ pain, and requires the pre-approval of the U.S. Drug Enforcement

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Katherine Whitehead Miller, The US FTC seeks divestiture of rights and assets to five different medications before approving a merger affecting the markets for generic injectable pharmaceuticals (Hospira / Mayne), 21 May 2007, e-Competitions May 2007, Art. N° 53067

Visites 231

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues